Premium
Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
Author(s) -
Urbiola Carles,
Santer Frédéric R.,
Petersson Monika,
van der Pluijm Gabri,
Horninger Wolfgang,
Erlmann Patrik,
Wollmann Guido,
Kimpel Janine,
Culig Zoran,
von Laer Dorothee
Publication year - 2018
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31556
Subject(s) - oncolytic virus , vesicular stomatitis virus , prostate cancer , virotherapy , virology , virus , interferon , vesicular stomatitis , cancer research , prostate , medicine , cancer , lymphocytic choriomeningitis , immunology , biology , immune system , cd8
Oncolytic viruses, including the oncolytic rhabdovirus VSV‐GP tested here, selectively infect and kill cancer cells and are a promising new therapeutic modality. Our aim was to study the efficacy of VSV‐GP, a vesicular stomatitis virus carrying the glycoprotein of lymphocytic choriomeningitis virus, against prostate cancer, for which current treatment options still fail to cure metastatic disease. VSV‐GP was found to infect 6 of 7 prostate cancer cell lines with great efficacy. However, susceptibility was reduced in one cell line with low virus receptor expression and in 3 cell lines after interferon alpha treatment. Four cell lines had developed resistance to interferon type I at different levels of the interferon signaling pathway, resulting in a deficient antiviral response. In prostate cancer mouse models, long‐term remission was achieved upon intratumoral and, remarkably, also upon intravenous treatment of subcutaneous tumors and bone metastases. These promising efficacy data demonstrate that treatment of prostate cancer with VSV‐GP is feasible and safe in preclinical models and encourage further preclinical and clinical development of VSV‐GP for systemic treatment of metastatic prostate cancer.